These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19195431)

  • 21. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does tenofovir influence efavirenz pharmacokinetics?
    Rotger M; Colombo S; Furrer H; Décosterd L; Buclin T; Telenti A
    Antivir Ther; 2007; 12(1):115-8. PubMed ID: 17503755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
    Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
    Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
    Adusumilli S
    Drugs Today (Barc); 2009 Sep; 45(9):679-85. PubMed ID: 19956809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.
    Kruse G; Esser S; Stocker H; Breske A; Koerber A; Kopperman M; Wiehler H; Ross B; Möcklinghoff C; Hill A; Becker M; Kurowski M
    Antivir Ther; 2005; 10(2):349-55. PubMed ID: 15865230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
    Mitchell D; Israr M; Alam S; Dinello D; Kishel J; Jia R; Meyers C
    HIV Med; 2014 Apr; 15(4):196-202. PubMed ID: 24580719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tenofovir on didanosine absorption in patients with HIV.
    Pecora Fulco P; Kirian MA
    Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
    Bongiovanni M; Tordato F
    Curr Med Chem; 2006; 13(23):2789-93. PubMed ID: 17073629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
    J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
    Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
    AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
    [No Abstract]   [Full Text] [Related]  

  • 38. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Buti M; Homs M
    Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):413-21. PubMed ID: 22928893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
    Stephan C
    Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
    TreatmentUpdate; 2003; 15(3):4-5. PubMed ID: 17216846
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.